- Repros Therapeutics (RPRX) reports six-month interim results from a study of "Androxal treatment of secondary hypogonadal men and its effect on bone mineral density."
- No bone loss was observed compared to placebo.
- Some improvement in bone mineral density was observed in the Androxal group.
- Topline, 12-month results are due in Q2 2014. (PR)
- Shares +0.9% AH.